InsiderTrades.com logo

CDT Insider Trading

Insider Ownership Percentage: 30.93%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,446,981.00

Conduit Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Conduit Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Conduit Pharmaceuticals Share Price & Price History

Current Price: $1.09
Price Change: ▲ Price Increase of +0.08 (7.92%)
As of 03/14/2025 05:00 PM ET

This chart shows the closing price history over time for CDT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Conduit Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/7/2024Ltd NirlandMajor ShareholderSell9,390$10.00$93,900.0060,920View SEC Filing Icon  
10/4/2024Ltd NirlandMajor ShareholderSell13,689$10.00$136,890.0070,310View SEC Filing Icon  
10/2/2024Ltd NirlandMajor ShareholderSell3,331$10.00$33,310.0099,000View SEC Filing Icon  
9/30/2024Ltd NirlandMajor ShareholderSell10,168$12.00$122,016.00114,831View SEC Filing Icon  
7/17/2024Andrew ReganDirectorSell15,141$26.00$393,666.001,776View SEC Filing Icon  
7/15/2024Andrew ReganDirectorSell10,052$25.00$251,300.00119,361View SEC Filing Icon  
7/12/2024Andrew ReganDirectorSell13,898$25.00$347,450.00129,413View SEC Filing Icon  
7/10/2024Andrew ReganDirectorSell1,500$33.00$49,500.00152,140View SEC Filing Icon  
7/8/2024Andrew ReganDirectorSell359$51.00$18,309.00154,417View SEC Filing Icon  
7/3/2024Andrew ReganDirectorSell10$64.00$640.00154,776View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Conduit Pharmaceuticals (NASDAQ:CDT)

3.29% of Conduit Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Conduit Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/17/2025Citadel Advisors LLC526,268$36K0.0%+177.0%51.094%Search for SEC Filing on Google Icon
2/13/2025Barclays PLC892,350$61K0.0%+6.5%86.636%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC584,984$40K0.0%+36.8%56.795%Search for SEC Filing on Google Icon
1/30/2025Rhumbline Advisers1,028,702$71K0.0%+5,034.0%1.000%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Conduit Pharmaceuticals logo
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.
Read More on Conduit Pharmaceuticals

Today's Range

Now: $1.09
Low: $1.01
High: $1.12

50 Day Range

MA: $3.46
Low: $1.01
High: $12.00

52 Week Range

Now: $1.09
Low: $0.98
High: $392.00

Volume

524,307 shs

Average Volume

983,785 shs

Market Capitalization

$3.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.3

Who are the company insiders with the largest holdings of Conduit Pharmaceuticals?

Conduit Pharmaceuticals' top insider investors include:
  1. Andrew Regan (Director)
  2. Ltd Nirland (Major Shareholder)
Learn More about top insider investors at Conduit Pharmaceuticals.

Who are the major institutional investors of Conduit Pharmaceuticals?

Conduit Pharmaceuticals' top institutional shareholders include:
  1. Rhumbline Advisers — 1.00%
  2. Barclays PLC — 86.64%
  3. Geode Capital Management LLC — 56.79%
  4. Citadel Advisors LLC — 51.09%
Learn More about top institutional investors of Conduit Pharmaceuticals stock.

Which major investors are buying Conduit Pharmaceuticals stock?

In the previous quarter, CDT stock was purchased by institutional investors including:
  1. Rhumbline Advisers
  2. Citadel Advisors LLC
  3. Geode Capital Management LLC
  4. Barclays PLC